Last updated on November 2019

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Brief description of study

To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia

Clinical Study Identifier: NCT03121586

Find a site near you

Start Over

CNS Research Science, Inc.

Jamaica, NY United States
  Connect »

Synexus Clinical Research, Inc.

Jamaica, NY United States
  Connect »

Neurobehavioral Research, Inc.

Cedarhurst, NY United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.